The Reflux Test That Hurt 184 People: Inside Medtronic's Bravo Capsule Recall
The Food and Drug Administration classified Medtronic's Bravo capsule recall as Class I — its most serious category — after 184 serious injuries were reported when the reflux-testing capsule failed to attach to the oesophagus or detach from its delivery device as intended.
- 184 serious injuries, no deaths: the reports Medtronic had made to the FDA as of August 10, 2026, for the 2026 Bravo capsule issue.
- September 15, 2026: the date the FDA classified the recall as Class I, following its August 27, 2026 early alert.
- FGS-0635 and FGS-0636: the affected product numbers — the five-pack and the one-pack — with expiration dates through October 20, 2027.
- 33 serious injuries: the reports tied to the separate June 2025 Bravo recall, caused by misapplied adhesive rather than the 2026 deployment-component fault.
- GERD: gastroesophageal reflux disease, the condition the Bravo capsule test is designed to help diagnose by measuring acid in the oesophagus.
Background explainers on cases like this appear on the Problem Solved channel.
What the Bravo Capsule Is Supposed to Do
Gastroesophageal reflux disease, universally shortened to GERD, is the condition in which stomach acid repeatedly flows back into the oesophagus, the muscular tube between mouth and stomach. Diagnosing it is not always straightforward: symptoms overlap with other conditions, and doctors often want an objective measurement of how often acid reaches the oesophagus and whether it matches the patient's symptoms.
That is what the Bravo system does. A doctor attaches a small capsule to the oesophagus wall during an endoscopy-style procedure. The capsule measures pH — a scale of acidity, lower meaning more acidic — and transmits readings to a waist recorder, while the patient logs symptoms so the doctor can match symptoms to acid episodes. After a few days the capsule is designed to detach and pass naturally. The test is attractive because it is brief, needs no hospital stay, and avoids a nasal catheter — which is why a delivery failure matters so much.
What Went Wrong in the 2026 Recall
The FDA's most serious recall category is Class I. A Class I recall is used when there is a reasonable probability that use of a product will cause serious adverse health consequences or death. The agency issued an early alert about the Bravo capsule delivery device on August 27, 2026, warning of a potentially high-risk device issue, and on September 15, 2026 it classified the recall as Class I.
The fault, as Medtronic described it, lies in the component controlling capsule deployment. The capsule may fail to attach to the oesophagus, or fail to detach from the delivery device. Either failure can turn a diagnostic procedure into an emergency: the capsule can be inhaled, block the airway, perforate or cut the oesophagus, cause bleeding, remain as a foreign object, or delay the diagnosis itself. Medtronic also lists chest pain, and says the problem worsens when the delivery device is not kept perfectly straight during insertion, as its guide instructs.
The recall covers Bravo CF capsule delivery devices with product numbers FGS-0635 (the five-pack) and FGS-0636 (the one-pack), with expiration dates through October 20, 2027. The FDA directs health care providers to stop using affected devices and return unused recalled products to Medtronic, and Medtronic can be reached at 800-448-3644, option 3, for adverse reactions, quality problems, or questions about the recall.
The 184 Injuries — and What That Number Does and Does Not Prove
As of August 10, 2026, Medtronic had reported 184 serious injuries associated with the issue and no deaths. That figure is the single most quoted number in the recall, and it deserves careful reading. Adverse event reports are reports, not court findings: a report records that an injury occurred in connection with a device, not a proven conclusion that the device caused that injury in that patient. The FDA itself cautions that adverse event reports alone cannot establish causation or show how often an injury occurs.
That caution cuts both ways. No one should quote 184 as proven device-caused injuries — nor dismiss the number, because Class I follows only after the agency judges a reasonable probability of serious harm. The honest reading: 184 reported serious injuries, no reported deaths, for a failure mode inherently capable of causing exactly the injuries listed. For a patient, the relevant question is simply whether the device planned for their procedure is an affected unit.
The 2025 Recall Was Different — and That Distinction Matters
Patients and hospitals that remember a Bravo recall from last year are remembering a different fault. In June 2025, Medtronic recalled the same product numbers after misapplied adhesive during manufacturing was found to prevent the capsule from attaching or detaching properly; that recall was associated with 33 reported serious injuries and no deaths. The 2026 recall traces to a different root cause — the deployment component — and the FDA's escalation to Class I in September 2026 was the second most-serious action on the same device in just over a year.
The distinction matters practically. A hospital that cleared its 2025 adhesive lots cannot assume remaining stock is safe: the 2026 action covers devices by product number and expiration date, not by old adhesive lots. And a patient injured in 2025 faces different evidence questions from one injured in 2026, because the manufacturing records and warnings for each fault differ.
What Patients and Hospitals Should Do Now
If you are scheduled for a Bravo test, ask before the procedure: is the device planned for my test a recalled unit — FGS-0635 or FGS-0636, expiring through October 20, 2027? If yes, or if staff cannot confirm otherwise, ask what alternative the doctor proposes. If you already had a Bravo test and then had severe chest pain, swallowing difficulty, breathing trouble, or bleeding, seek urgent care and tell the team about the Bravo procedure and its date.
Hospitals should quarantine all unused affected product, return it to Medtronic for replacement or credit, and complete the customer confirmation form even with no unused inventory — that is how Medtronic accounts for every unit. Procedure records matter: the product number, lot, and expiration date actually used, with the procedure note and complication record, are what connect a patient to a recalled unit. Report adverse events to the FDA's MedWatch program as well as to Medtronic.
Who Benefits From This — and Who Does Not
People who had a Bravo test with an affected unit and suffered a listed complication — aspiration, perforation, airway obstruction, bleeding, a retained capsule, or delayed diagnosis — benefit most, because device identification plus procedure records are the foundation of any product-liability claim, and lawyers are already reviewing Bravo injury cases. Hospitals holding unused affected stock benefit too: the recall gives a clear quarantine-and-return path before another patient is exposed.
People who had a successful Bravo test with no complication do not gain a claim from this recall; a recalled device that worked as intended and caused no harm is a reason to be informed, not a basis for compensation. And people with reflux symptoms who have never had a Bravo test gain nothing legally from the recall — though they may reasonably ask their doctor whether a different diagnostic method suits them. For a sense of how another Medtronic recall was handled before any device reached a patient, see the OmniaSecure lead recall and its quarantine-and-return process.
One related caution: a perforated oesophagus is a medical emergency whatever caused it, and the warning signs are easy to miss. Readers who want to know what clinicians look for should read the signs of a missed oesophageal perforation and the repair clock.
Frequently Asked Questions
What is the Medtronic Bravo capsule recall?
It is a Class I recall — the FDA's most serious category — of Bravo CF capsule delivery devices used in reflux testing, because the capsule may fail to attach to the oesophagus or detach from its delivery device as intended.
Who benefits from knowing about this recall?
People who had a Bravo test with an affected unit and suffered a listed complication benefit most, because device identification and procedure records are the foundation of any injury claim, and hospitals holding unused affected stock benefit from the quarantine-and-return path.
Who does not benefit, or has no claim from this recall?
People who had a successful Bravo test with no complication, and people with reflux symptoms who never had a Bravo test, gain no legal claim from this recall, even though they may reasonably ask about alternative diagnostic methods.
How do I benefit, or how do I start checking my Bravo test?
Ask whether your device was product FGS-0635 or FGS-0636 with an expiration date through October 20, 2027, gather your procedure note and the device product and lot details, seek urgent care for severe chest pain, swallowing difficulty, or breathing trouble, and speak with a product-liability lawyer about your records.
How many injuries were reported, and were there deaths?
Medtronic reported 184 serious injuries and no deaths associated with the 2026 issue as of August 10, 2026; those are adverse event reports, which record that an injury occurred in connection with a device rather than proving the device caused each injury.
Is the 2026 recall the same as the 2025 Bravo recall?
No. The June 2025 recall involved misapplied adhesive and 33 reported serious injuries, while the 2026 recall involves a faulty capsule-deployment component and is the second most-serious action on the same device in just over a year.
This article is general information about a court ruling and a device recall, not legal or medical advice. If you believe you were harmed, speak promptly with a qualified lawyer or clinician about your own facts and deadlines.